40 / 84
280
Ces Urol 2015; 19(4): 270–280
PŘEHLEDOVÝ ČLÁNEK
40. Muramaki M, So A, Hayashi N, et al.
Chemosensitization of gemcitabine-resistant human bladder
cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene,
clusterin. BJU Int 2009 Feb; 103(3): 384–390.
41. Siegsmund MJ, Marx C, Seemann O, et al.
Cisplatin-resistant bladder carcinoma cells: enhanced
expression of metallothioneins. Urol Res 1999 Jun; 27(3): 157–163.
42. Byun SS, Kim SW, Choi H, Lee C, Lee E.
Augmentation of cisplatin sensitivity in cisplatin-resistant
human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme
activities. BJU Int 2005 May; 95(7): 1086–1090.
43. Hour TC, Lai YL, Kuan CI, et al.
Transcriptional up-regulation of SOD1 by CEBPδ: a potential target for
cisplatin resistant human urothelial carcinoma cells. Biochem Pharmacol 2010 Aug 1; 80(3): 325–334.
44. Kim JK, Kim KD, Lee E, et al.
Up-regulation of Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant
human bladder cancer cell line. Cancer Lett 2004 Aug 20; 212(1): 61–70.
45. Lee S, Yoon CY, Byun SS, Lee E, Lee SE.
The role of c-FLIP in cisplatin resistance of human bladder
cancer cells. J Urol 2013 Jun; 189(6): 2327–2334.
46. Yu HM, Wang TC.
Mechanism of cisplatin resistance in human urothelial carcinoma cells. Food Chem
Toxicol 2012 May; 50(5): 1226–1237.
47. Tsunoda T, Koga H, Yokomizo A, et al.
Inositol 1,4,5-trisphosphate (IP3) receptor type1 (IP3R1) modulates
the acquisition of cisplatin resistance in bladder cancer cell lines. Oncogene 2005 Feb; 24(8): 1396–1402.
48. Miura N, Takemori N, Kikugawa T, et al.
Adseverin: a novel cisplatin-resistant marker in the human
bladder cancer cell line HT1376 identified by quantitative proteomic analysis. Mol Oncol 2012 Jun; 6(3):
311–322.
49. Meng Q, Lei T, Zhang M, et al.
Identification of proteins differentially expressed in adriamycin-resistant
(pumc-91/ADM) and parental (pumc-91) human bladder cancer cell lines by proteome analysis. J Cancer
Res Clin Oncol 2013 Mar; 139(3): 509–519.
50. Greife A, Tukova J, Steinhoff C, et al.
Establishment and characterization of a bladder cancer cell line
with enhanced doxorubicin resistance by mevalonate pathway activation. Tumour Biol. 2015 May; 36(5):
3293–3300.
51. Yeganeh B, Wiechec E, Ande SR.
Targeting the mevalonate cascade as a new therapeutic approach
in heart disease, cancer and pulmonary disease. Pharmacol Ther 2014 Jul; 143(1): 87–110.
52. Clendening JW, Penn LZ.
Targeting tumor cell metabolism with statins. Oncogene 2012 Nov; 31(48):
4967–4978.
53. Kornblau SM, Banker DE, Stirewalt D, et al.
Blockade of adaptive defensive changes in cholesterol
uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1
study. Blood 2007 Apr; 109(7): 2999–3006.